SUSTAIN-6 documented absolute rates of 3.0% for retinopathy complications with semaglutide versus 1.8% with placebo. This discrepancy between the current post-marketing findings and prior clinical ...

real-world data after initiation of semaglutide treatment Poster presentation (PO4.095) Quantifying the Productivity Gains of Semaglutide Treatment in the UK for the Population Eligible for ...